Moro D, Villemain D, Vuillez J P, Delord C A, Brambilla C
Department of Respiratory Medicine, Hospital A. Michallon BP217X, Grenoble, France.
Lung Cancer. 1995 Oct;13(2):169-76. doi: 10.1016/0169-5002(95)00485-8.
CEA, SCC and CYFRA 21-1 were measured in samples of serum coming from 105 'Non small cell lung cancer' (NSCLC) patients. The present study has been carried out to compare these markers, to analyse their prognostic significance and to determine the best combination of tumor markers. The median value and interquartile range were: CYFRA 21-1: 2,3 ng/ml, CEA: 3,7 ng/ml, SCC: 1,2 ng/ml. CEA demonstrated higher values in adenocarcinomas (P = 0.04). SCC and CYFRA 21-1 were comparable in the different histologic groups. CYFRA 21-1 and CEA values were dependant on tumor stage. Advanced tumors (T3 and T4) demonstrated higher serum CYFRA 21-1 level (P = 0.0006). CYFRA 21-1 was higher than 3,3 ng/ml in 36% of patients. CEA was higher than 5 ng/ml in 38% of patients and SCC was higher than 2 ng/ml in 27% of patients. Patients with a high CEA and CYFRA21-1 serum level had a shorter survival than those with a normal serum level. In a Cox regression analysis four variables (TNM stage, age, CYFRA 21-1 and CEA level) were found to be significant in the prediction of survival; CYFRA 21-1 level had the lowest P value (P = 0.0002). The current study suggests the use of a combination of CEA and CYFRA 21-1 in the clinical care of NSCLC.
对105例“非小细胞肺癌”（NSCLC）患者的血清样本进行了癌胚抗原（CEA）、鳞状细胞癌抗原（SCC）和细胞角蛋白19片段（CYFRA 21-1）检测。本研究旨在比较这些标志物，分析其预后意义，并确定肿瘤标志物的最佳组合。中位数和四分位间距分别为：CYFRA 21-1：2.3 ng/ml，CEA：3.7 ng/ml，SCC：1.2 ng/ml。CEA在腺癌中的值较高（P = 0.04）。SCC和CYFRA 21-1在不同组织学组中具有可比性。CYFRA 21-1和CEA的值取决于肿瘤分期。晚期肿瘤（T3和T4）的血清CYFRA 21-1水平较高（P = 0.0006）。36%的患者CYFRA 21-1高于3.3 ng/ml。38%的患者CEA高于5 ng/ml，27%的患者SCC高于2 ng/ml。血清CEA和CYFRA21-1水平高的患者生存期短于血清水平正常的患者。在Cox回归分析中，发现四个变量（TNM分期、年龄、CYFRA 21-1和CEA水平）对生存预测具有显著意义；CYFRA 21-1水平的P值最低（P = 0.0002）。本研究建议在NSCLC的临床护理中联合使用CEA和CYFRA 21-1。
